ADIL Adial Pharmaceuticals Inc

1.59
+0.13  (+9%)
Previous Close 1.46
Open 1.46
Price To Book 1.62
Market Cap 16,285,494
Shares 10,242,449
Volume 20,406
Short Ratio
Av. Daily Volume 42,733

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due in 2020. Data from second Phase 3 trial for U.S. required endpoint due 2022.
AD04
Alcohol use disorder

Latest News

  1. Adial Pharmaceuticals' Chief Executive Officer to be Featured Live on Cheddar's ''Closing Bell''
  2. Do Directors Own Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Shares?
  3. Adial Pharmaceuticals' Chief Medical Officer Presents AD04 at the Scientific Federation 7th World Congress on Nursing & Healthcare
  4. Adial Pharmaceuticals Receives Notification Prior to Acceptance of Israeli Patent for AD04 in Alcohol Use Disorder
  5. Adial Pharmaceuticals and Tedor Pharma Announce Collaboration to Manufacture AD04 Through Commercialization
  6. Adial Pharmaceuticals Announces Collaboration Agreement with Eurofins for Genetic Biomarker Testing to Support Upcoming Phase 3 Clinical Trial for Alcohol Use Disorder
  7. Adial Pharmaceuticals CEO to Present at the ThinkEquity Conference on May 2nd in New York City
  8. Have Insiders Been Buying Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Shares This Year?
  9. Adial Pharmaceutical's Chief Medical Officer Dr. Bankole Johnson Featured on NBC West Palm Beach, Florida Affiliate
  10. Adial Pharmaceuticals Announces Appointment of Alex Lugovoy as Head of Strategy
  11. Bankole A. Johnson, M.D., Chief Medical Officer of Adial Pharmaceuticals Delivers Keynote Lecture; Receives Prestigious American Society of Addiction Medicine Award
  12. Adial Pharmaceuticals Announces Open Market Purchases of Common Stock by Chief Medical Officer, Bankole Johnson, M.D.
  13. Adial Pharmaceuticals Announces Appointment of Bankole Johnson, M.D., as Chief Medical Officer
  14. Adial Pharmaceuticals Announces Filing to Update the Prior Registration Statement Registering the Shares Underlying the ADILW Warrants
  15. Adial CEO: A Medical Solution For Alcoholism Could Be Just Around The Corner
  16. Adial Pharmaceuticals Featured on CBS in San Francisco
  17. Adial Pharmaceuticals Announces Closing of $9.2 Million Underwritten Public Offering and Exercise of Underwriters’ Over-Allotment Option
  18. Four Biotech Stocks Setting The Standard On Thursday (2/21/19)
  19. Adial Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering
  20. Adial Pharmaceuticals Announces Partnership with Catalent to Package and Distribute Adial’s AD04 for its Phase 3 Trial